20-F: Sanofi Reports Strong 2025 Growth Driven by Dupixent, Strategic M&A

Sanofi's 2025 annual report highlights robust net sales growth, fueled by Dupixent and strategic acquisitions, despite significant R&D setbacks and ongoing generic competition.

Summary

• Net sales for 2025 reached 43,626 million euros, a 6.2% increase on a reported basis and 9.9% at constant exchange rates (CER) compared to 2024.
• Net income attributable to equity holders of Sanofi increased by 40.5% to 7,813 million euros in 2025, up from 5,560 million euros in 2024.
• Business net income rose 7.2% to 9,555 million euros, with Business earnings per share (EPS) increasing 10.0% to 7.83 euros.
• Research and development (R&D) expenses increased by 6.1% to 7,842 million euros in 2025, representing 18.0% of net sales.
• Dupixent continued its strong performance, generating 15,714 million euros in net sales, up 25.2% CER, driven by demand across its approved indications.
• The company completed several strategic acquisitions in 2025, including Dren-0201, Inc., Vigil Neuroscience, Inc., Blueprint Medicines Corporation, and Vicebio Ltd., enhancing its immunology and neurology pipelines.
• Sanofi divested a 50% controlling stake in its consumer healthcare business, Opella, to Clayton, Dubilier & Rice (CD&R) on April 30, 2025, recognizing a net gain of 2.6 billion euros and receiving 10.4 billion euros in net cash proceeds.
• An impairment loss of 1,663 million euros was recognized on tolebrutinib, a multiple sclerosis drug candidate, due to reduced approval probability following negative Phase 3 study results and regulatory interactions.
• Paul Hudson's mandate as Chief Executive Officer will not be renewed, effective February 17, 2026, with Belén Garijo appointed as his successor after the Annual General Meeting on April 29, 2026.
• Sanofi entered into a voluntary Most Favored Nation (MFN) agreement with the US government on December 19, 2025, committing to align Medicaid prices for certain medicines with other high-income countries, expecting an average reduction of 61% for specific treatments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a generally positive report, reflecting strong performance in key growth drivers and proactive strategic acquisitions. However, significant R&D setbacks and ongoing pricing pressures temper the overall sentiment, indicating a mixed but forward-looking trajectory.

Positives

• Net sales increased by 6.2% on a reported basis and 9.9% at constant exchange rates (CER) to 43,626 million euros in 2025.
• Net income attributable to equity holders of Sanofi grew 40.5% to 7,813 million euros.
• Business net income increased 7.2% to 9,555 million euros, and Business EPS rose 10.0% to 7.83 euros.
• Dupixent sales surged by 25.2% CER to 15,714 million euros, driven by strong demand across its approved indications.
• ALTUVIIIO sales grew 77.6% CER to 1,160 million euros, driven by patient switching from older hemophilia A treatments.
• Successful launches of Wayrilz (immune thrombocytopenia) and Qfitlia (hemophilia A and B) in the US market in 2025.
• Strategic acquisitions of Dren-0201, Inc., Vigil Neuroscience, Inc., Blueprint Medicines Corporation, and Vicebio Ltd. strengthened the immunology and neurology pipelines.
• The divestment of Opella generated a net gain of 2.6 billion euros and a net cash inflow of 10.4 billion euros.
• Selling and general expenses as a percentage of net sales decreased to 21.9% in 2025 from 22.4% in 2024, reflecting improved operational efficiency.
• Sanofi Ventures announced an additional 625 million dollar multi-year capital commitment, increasing total assets under management to over 1.4 billion dollars.
• The company's share repurchase program was executed in full by the end of 2025, with 51,380,928 shares repurchased for approximately 5 billion euros.

Negatives

• Sales erosion from generic and biosimilar competition continued to impact key products, with a year-on-year loss of 353 million euros in net sales for affected products.
• Lantus sales in Europe decreased by 12.4% CER, and Lovenox sales were down 14.4% CER due to increasing competition.
• Aubagio sales declined 35.4% CER due to loss of exclusivity in the US (March 2023) and Europe (September 2023).
• Mozobil sales decreased by 54.1% CER due to generic competition in the US (July 2023) and Europe (early 2024).
• An impairment loss of 1,663 million euros was recognized on tolebrutinib, a multiple sclerosis drug candidate, reflecting reduced probability of approval.
• Further development on a vaccine candidate for extraintestinal pathogenic E. coli was discontinued in 2025 due to insufficient efficacy, resulting in a 239 million euro impairment loss in 2024.
• The SP0125 program for RSV-related disease in toddlers was discontinued.
• Mixed results were reported for the itepekimab COPD Phase 3 studies in May 2025.
• Several other R&D programs were removed from the pipeline, including eclitasertib, SAR443579, SAR444656, SAR444881, SAR445514, SAR446159, SAR447873, and SP0237.
• Influenza and COVID-19 vaccine sales were down 5.8% CER in a contracted market, impacted by price reductions in Germany and soft vaccination rates in the US.
• Beyfortus sales in the US were down 27.9% CER due to a high base effect and existing inventory levels at the beginning of the season.
• Operating income decreased to 6,344 million euros in 2025 from 7,252 million euros in 2024, mainly due to increased impairment losses on intangible assets.

Risks

• Product liability claims, such as those related to Taxotere, Zantac, Talc products, and Depakine, could adversely affect business, results of operations, and financial condition.
• Failure to comply with extensive and significant government legislation and regulations, including evolving data privacy and cybersecurity rules, could result in financial penalties and reputational harm.
• Research, clinical development, and regulatory approval processes present significant risks, including setbacks or failures in pipeline projects, delays in marketing approval, and unexpected adverse events.
• The pricing and reimbursement of medicines and vaccines are negatively affected by increasing cost containment pressures, including US federal government drug price controls (MFN, IRA) and stricter health technology assessment (HTA) processes in Europe.
• Breaches of data security, disruptions of information technology systems, and cyber threats could result in financial, legal, competitive, operational, business, or reputational harm.
• The manufacture of medicines and vaccines is technically complex, and supply interruptions, product recalls, or inventory losses caused by unforeseen events may reduce sales and delay launches.
• A substantial share of sales and income depends on the performance of certain key medicines and vaccines, making the company vulnerable to problems affecting these products.
• Reliance on third parties for discovery, manufacture, marketing, and distribution of some medicines and vaccines exposes the company to risks of non-performance or conflicts with partners.
• The company is subject to the risk of non-payment by customers, particularly in emerging markets and with public or subsidized health systems.
• Global economic conditions and an unfavorable financial environment, including geopolitical conflicts and inflation, could negatively affect the global pharmaceutical market's growth and Sanofi's business.
• A failure in crisis and business continuity management processes in case of unpredictable events (e.g., cyber-attacks, pandemics, natural disasters) could have negative consequences.
• Climate change or legal, regulatory, or market measures to address climate change may negatively affect business and results of operations.
• The use of social media platforms and communication technologies presents risks and challenges for business and reputation.
• Data sovereignty regulations increasingly restrict cross-border data flows, impacting global operations and strategic initiatives.
• Failure to successfully identify external business opportunities or realize anticipated benefits from strategic investments or divestments could adversely affect growth objectives.
• The globalization of business exposes the company to increased risks in specific areas, such as legal, regulatory, and political instability in emerging markets, and potential trade restrictions (e.g., proposed federal BIOSECURE Act in the US).

Future Outlook

Sanofi intends to continue increasing its investment in R&D, focusing on immunology, rare diseases, neurology, oncology, and vaccines. The company anticipates continued sales erosion from generic competition in 2026 for products like Lantus, Lovenox, Aubagio, and Mozobil. New EU pharmaceutical legislation is expected in early 2026, and the acquisition of Dynavax Technologies Corporation is projected to close in the first quarter of 2026. Belén Garijo is set to assume the role of Chief Executive Officer after the Annual General Meeting on April 29, 2026.

Management Comments

• Paul Hudson's mandate as Chief Executive Officer will not be renewed, effective February 17, 2026, and the Board thanks him for his valuable contributions to the transformation and development of the Group over the last six years.
• Belén Garijo has been appointed as Chief Executive Officer, effective after the Annual General Meeting on April 29, 2026, based on her international executive role, expertise, strategic vision in the pharmaceutical industry, and ability to drive value-creating transformations.
• Olivier Charmeil, Executive Vice President, General Medicines, will serve as Interim Chief Executive Officer during the transition period starting February 18, 2026.
• Manuela Buxo has been nominated as Executive Vice President, Specialty Care, effective March 1, 2026, succeeding Brian Foard.

Industry Context

StockSavvy.ai notes that the pharmaceutical industry is navigating a complex environment characterized by increasing cost containment pressures from governments and payers, particularly in the US with the implementation of the Most Favored Nation (MFN) policy and the Inflation Reduction Act (IRA). Europe is also undergoing significant regulatory reforms (EU Pharma Package, EU HTA Regulation) that are reshaping market access and pricing. The industry is seeing a rapid acceleration in biopharma innovation, with China emerging as a key hub for R&D and new drug approvals. The increasing adoption of AI and digital technologies is transforming drug discovery, clinical trials, and manufacturing processes across the sector, driving both efficiency and new ethical considerations.

Comparison to Industry Standards

• Sanofi's R&D expenditure of 18.0% of net sales in 2025 is a significant investment, aligning with the industry trend of increasing R&D productivity to compensate for patent expirations and generic competition.
• The company's focus on immunology, rare diseases, neurology, oncology, and vaccines positions it in high-growth therapeutic areas, similar to strategies adopted by other leading global pharmaceutical companies facing patent cliffs by 2030.
• Sanofi's experience with the US MFN agreement and IRA pricing policies reflects broader industry challenges, as these policies are expected to compress margins and shorten product lifecycles across the US market, impacting all major pharmaceutical players.
• The company's efforts in digital transformation and AI integration, including partnerships with firms like Formation Bio and OpenAI, are consistent with industry-wide trends to leverage advanced technologies for accelerating drug development and optimizing operations.
• The increasing scrutiny on drug pricing and reimbursement criteria, as seen in the EU HTA Regulation and US policies, indicates a rising bar for market entry and demands for real-life outcomes, a challenge faced by all innovative pharmaceutical companies.

Management Changes

Corporate Governance

Legal Proceedings

• Sanofi Pasteur Hepatitis B Vaccine Product Litigation: One ongoing lawsuit in France related to alleged neurological disorders and autoimmune diseases.
• Taxotere Product Litigation in the US: Sanofi is near the end of settlement process for thousands of lawsuits alleging personal injuries, with approximately 250 plaintiffs opting out for continued litigation.
• Zantac Litigation in the US: MDL Court dismissed cases in December 2022, but approximately 7,900 plaintiffs appealed. Delaware State Court initially allowed plaintiff experts but was reversed by the Delaware Supreme Court in July 2025. Sanofi reached settlement agreements for a majority of Delaware cases in April 2025 and for most other state court cases in March 2024. Approximately 18,765 individual product liability plaintiffs remain.
• Zantac Litigation in Canada: Seven proposed class actions and 124 individual claims are ongoing. British Columbia court dismissed action in May 2023, Quebec proceedings stayed pending US MDL appeal.
• Talc Product Litigation in the US: Approximately 1,200 ongoing product liability actions alleging asbestos presence in talc products; no cases have proceeded to trial.
• Depakine Product Litigation in France: 82 families (136 people) have civil claims. A class action lawsuit is pending appeal. A criminal investigation for aggravated deception, involuntary injuries, and involuntary manslaughter is ongoing. A public compensation scheme is in place, with Sanofi opposing ONIAM's reimbursement claims. Paris Administrative Court of Appeal issued five rulings in January 2025, and Versailles Administrative Court of Appeal issued one in February 2025, with varying liability findings.
• Depakine Product Litigation in other EU countries, UK, and Switzerland: Ongoing civil and criminal proceedings in Switzerland, Spain, Belgium, Ireland, and the United Kingdom.
• Dengvaxia Product Litigation in the Philippines: Several criminal actions are pending, with the Court dismissing the first eight criminal cases in July 2024. Four additional criminal cases were filed in 2025.
• Praluent (alirocumab)-related Amgen Patent Litigation in the US: US Supreme Court ruled in favor of Sanofi and Regeneron in May 2023, closing these matters.
• Praluent (alirocumab)-related Amgen Patent Litigation in Europe: Amgen filed infringement action in Unified Patent Court (UPC) in June 2023. Sanofi's revocation action was initially successful but reversed on appeal in November 2025. EPO found Amgen's patent valid in May 2025, currently under appeal.
• Plavix (clopidogrel) Attorney General Action in Hawaii: Settled in May 2025, with Sanofi US paying 350 million dollars.
• Plavix (clopidogrel) Attorney General Action in Texas: Texas AG filed a complaint in November 2025 alleging violations of deceptive trade practices and healthcare program fraud acts.
• Plavix (clopidogrel)-related litigation in France: Paris Court of Appeal ordered Sanofi to pay CNAM approximately 150 million euros in damages; Sanofi filed an appeal to the French Supreme Court in November 2025.
• 340B Drug Pricing Program in the United States: Sanofi is involved in several matters, including an integrity initiative and a Credit or Rebate Model, facing legal challenges and ongoing HRSA review. Two active 340B Administrative Dispute Resolution (ADR) proceedings are ongoing.
• Mosaic Health in the United States: Antitrust class action complaint against Sanofi and other manufacturers, alleging conspiracy to eliminate favorable 340B pricing, remanded to District Court in August 2025.
• Adventist Health System/West in the United States: Sued several drug manufacturing companies, including Sanofi, alleging False Claims Act violations; plaintiffs filed an appeal after dismissal in March 2024.
• Antitrust investigation by the European Commission in France and Germany: Investigation initiated in September 2025 regarding seasonal flu vaccine space, based on a complaint by CSL Sequirus.
• Preliminary investigation by the Parquet national financier in France: Sanofi's headquarters visited in November 2025 as part of an investigation into a financing arrangement related to an acquisition more than 10 years ago, concerning allegations of money laundering, tax fraud, and criminal conspiracy.

Related Party Transactions

• Sanofi repurchased 29,556,650 shares from L'Oréal, a significant shareholder, for approximately 3 billion euros on February 2, 2025.
• Revenues generated from the manufacturing of Consumer Healthcare products on behalf of Opella entities (a related party since May 1, 2025) amounted to 120 million euros in 2025.
• Transactions between Sanofi and the associate OPAL JV Co (a related party since May 1, 2025) for the period from May 1, 2025 through December 31, 2025, included sales and other revenues of 3,346 million euros and net income of -622 million euros.
• Sanofi has a global strategic collaboration with Regeneron on monoclonal antibodies for the development and commercialization of Dupixent, Kevzara, and SAR440340 (REGN3500-itepekimab).
• Sanofi and AstraZeneca have an agreement to develop and commercialize Beyfortus (nirsevimab) for RSV prevention.

Stakeholder Impact

• Shareholders: Impacted by strong financial performance, share buybacks, proposed dividend increase, but also by R&D setbacks, legal liabilities, and potential stock price volatility due to CEO transition and market risks.
• Patients: Benefit from new product launches (Wayrilz, Qfitlia, Ayvakit) and pipeline advancements in immunology, rare diseases, and neurology. However, delays in regulatory approvals (tolebrutinib) and product liability concerns (Taxotere, Zantac, Depakine) pose risks to patient access and safety.
• Employees: Affected by ongoing restructuring and reorganization programs, including voluntary redundancy programs. The company's focus on talent retention and development, including AI skills, is crucial for future success. CEO transition and other management changes may impact morale and organizational stability.
• Customers (wholesalers, distributors, pharmacies, hospitals, government agencies): Face risks of non-payment, particularly in emerging markets. Pricing pressures from government programs (MFN, IRA) and PBMs impact commercial terms and access.
• Suppliers: Exposed to supply chain disruptions and potential changes in sourcing strategies due to geopolitical tensions and climate change risks.
• Regulatory Authorities: Engage with Sanofi on product approvals, manufacturing compliance, and pricing policies, reflecting the highly regulated nature of the pharmaceutical industry.
• Governments/Payers: Benefit from MFN agreements and IRA price negotiations aimed at reducing healthcare costs, but also face challenges in ensuring timely access to innovative medicines.

Next Steps

• Belén Garijo will assume the role of Chief Executive Officer after the Annual General Meeting on April 29, 2026.
• The acquisition of Dynavax Technologies Corporation is expected to close in the first quarter of 2026.
• Further analysis of itepekimab Phase 3 data and regulatory feedback is needed for its future development in COPD.
• Sanofi will pursue global regulatory filings for venglustat in Gaucher disease type 3 following positive Phase 3 results.
• A Phase 3 study for Dupixent in children aged two to six years suffering from asthma was initiated in 2024.
• A supplemental biologics license application (sBLA) for Dupilumab for the Allergic Fungal Rhinosinusitis (AFRS) indication is under priority review by the FDA, with a target action date of February 28, 2026.
• The new EU pharmaceutical legislation reform is anticipated to be adopted in the first quarter of 2026, with implementation foreseen by mid-2028.
• The first wave of Joint Clinical Assessment (JCA) reports under the EU HTA Regulation is expected in 2026, bringing clarity on the new process.
• Sanofi intends to implement an additional integrity initiative called the Credit or Rebate Model for the 340B drug pricing program, pending HRSA review.
• The company will continue to monitor and address ongoing legal proceedings related to product liability and patent infringement.

Key Dates

Recommendation

Sanofi's 2025 performance demonstrates strong growth in key innovative products like Dupixent and strategic M&A activities that bolster its pipeline. The Opella divestment provides significant cash inflow, which can be reinvested. However, the substantial impairment loss on tolebrutinib, ongoing R&D program discontinuations, and persistent generic erosion for mature products highlight inherent risks in pharmaceutical development and market dynamics. The CEO transition introduces a period of uncertainty, and the impact of evolving regulatory and pricing pressures (MFN, IRA) remains a significant headwind. While the long-term strategy appears sound, these challenges warrant a 'hold' recommendation, advising investors to monitor the successful integration of new acquisitions, the progress of the pipeline, and the effective navigation of the complex regulatory and competitive landscape before making further investment decisions.

Keywords

Pharmaceuticals, Biopharma, Vaccines, Immunology, Rare Diseases, Neurology, Oncology, Dupixent, ALTUVIIIO, R&D, SEC Filing, 20-F, Financial Results, Acquisitions, Divestments, Generics, Biosimilars, Regulatory Risks, Cybersecurity, Product Liability, Pricing Pressure, IRA, MFN, AI, Corporate Governance